Descripción del proyecto
La información sobre el desarrollo de las células cartilaginosas ofrece indicios para su reparación
El deterioro del cartílago articular debido a un traumatismo es frecuente y puede ser discapacitante. No obstante, las opciones de reparación son limitadas, ya que nuestra comprensión del desarrollo y el mantenimiento del cartílago articular es incompleta. Los científicos del proyecto ReSurface, financiado con fondos europeos, están estudiando los mecanismos moleculares que controlan el desarrollo y el mantenimiento de las células del cartílago articular. La idea es identificar los programas de transcripción que rigen la identidad y la actividad de las células específicas durante el desarrollo para determinar cuál es la fuente celular ideal para la reparación en adultos. Mediante una combinación de biología celular molecular y del desarrollo con técnicas de ingeniería avanzadas, los investigadores planean desarrollar una estrategia segura para llevar las células adecuadas al lugar que presenta un déficit de cartílago articular para favorecer la regeneración «in situ».
Objetivo
Repair of articular cartilage defects remains a significant clinical challenge due to gaps in our knowledge of articular cartilage development and maintenance in adulthood. This creates a lack of consensus on the ideal cell source for cell-based repair strategies and suitable methods of delivery. The overall goal of ReSurface is to develop a cell therapy platform for articular cartilage defect repair. This will be achieved by unravelling the molecular mechanisms controlling articular cartilage cell development and maintenance, generation of a panel of molecular parameters defining populations of cells that are safe and suitable for articular cartilage repair, and development of a minimally invasive method to deliver cells to the defect site. This project is highly multidisciplinary and intersectoral combining fundamental developmental and molecular cell biology with advanced engineering techniques and including significant industry and clinical collaboration throughout. This fellowship will have an outgoing phase at Dr April Craft’s Lab at Boston Children’s Hospital (BCH), affiliated with Harvard Medical School (HMS) and the Harvard Stem Cell Institute (HSCI), and a return phase to Prof Garry Duffy’s Lab at the National University of Ireland, Galway (NUIG) which is part of the Science Foundation Ireland funded Centre for Research in Medical Devices (CÚRAM). Clinical collaborators will include BCH, Brigham and Women’s Hospital, Boston, University College Hospital Galway (UCHG) and the Regenerative Medicine Institute (REMEDI) at NUIG while industry collaborators include Boston Scientific Limited (BSL). Having recently completed my PhD in biomaterials development, this project will diversify my professional competencies through advanced training with intersectoral and international collaborations and provide me with the scientific and transferable skills required for my transition to an independent scientist role.
Ámbito científico
Palabras clave
Programa(s)
Régimen de financiación
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinador
H91 Galway
Irlanda